RxDoctor Payments DataLook up a doctor →

Calvin Mein, MD

Ophthalmology · San Antonio, TXNPI 1164487617

Payments from drug & device makers

$1,299,970in general payments, 2019–2025

Across 535 payments — averaging $2429.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$454K
  • Novartis$449K
  • Apellis Pharmaceuticals, Inc.$267K
  • Regeneron$70K
  • AbbVie$29K
  • US Retina LLC$12K
  • plus $19K from 22 others
$1,321in research payments, 2019–2025

Across 8 payments — averaging $165.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$1K

What the payments were for

  • Consulting fees$6423%
  • Speaking & faculty fees$1,3906%
  • Travel & lodging$6032%
  • Food & beverage$10,22742%
  • Ownership interest$4,98320%
  • Other$6,65227%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer143$454,032
Novartis40$448,770
Apellis Pharmaceuticals, Inc.121$266,939
Regeneron92$70,447
AbbVie(2 entities)19$28,659
US Retina LLC11$11,635
Hexal AG5$10,375
Alimera Sciences, Inc.11$1,945
Alcon12$1,475
Regeneron Healthcare Solutions, Inc.25$1,318
Genentech USA, Inc.16$761
Onmark, Inc.2$642
Biotissue Holdings Inc.5$455
Dutch Ophthalmic, USA4$430
Eyepoint US, Inc.4$384
Astellas Pharma US Inc4$299
Carl Zeiss Meditec, Inc.1$206
Amgen1$150
Ocular Therapeutix, Inc.3$145
Biogen3$130
Dompe US, Inc.1$122
Optovue, Inc.1$120
Genentech, Inc.1$109
Sun Pharmaceutical Industries Inc.1$104
Aerie Pharmaceuticals, Inc.1$98
ANI Pharmaceuticals, Inc.2$97
Thrombogenics, Inc.4$74
Coherus Oncology, Inc.2$52

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,299,970 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas →

Medicare billing

Part B allowed, 2024
$4,364,045
Medicare patients
902
Services billed
31,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bromfenac Sodium47$5,403
Difluprednate49$4,712
Prednisolone Acetate129$4,466
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat101$1,717
Latanoprost37$791
Brimonidine Tartrate20$558
Ketorolac Tromethamine11$431
Tobramycin90$407
Timolol Maleate26$376
MoxifloxacinMoxifloxacin Hcl17$327

Paid to pharmacies, not to this prescriber.

Other ophthalmology in San Antonio

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →